Loading
A phase 3 trial of Nivolumab in melanoma, run by Amgen, active and no longer recruiting.
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma is a phase 3 interventional study registered as NCT06054555 by Amgen, with 633 participants enrolled, started 2023-11-02 and due to reach its primary completion in 2028-01-25. Interventions recorded: ABP 206, Nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Amgen, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Amgen, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/